Stay updated with breaking news from Term Liabilities. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today...
Q4 2021 revenue of $29.9 million, up 48% compared to Q4 2020Q4 2021 net loss of $5.1 million, compared to net loss of $18.2 million in Q4 2020Q4 2021 Adjusted EBITDA [1] of $1.9 millionFull year 2021 revenue
Press release content from Accesswire. The AP news staff was not involved in its creation.
24.03.2022 - - Confirmed partial response in one of the first three metastatic castration-resistant prostate cancer (mCRPC) patients treated with BPX-601 in Phase 1/2 study - - Favorable safety profile observed in initial dose cohort of BPX-603 in HER2+ solid ...
- Confirmed partial response in one of the first three metastatic castration-resistant prostate cancer patients treated with BPX-601 in Phase 1/2 study - - Favorable safety profile observed in... | March 24, 2022